Drug Repurposing and Computational Drug Discovery: Strategies and Advances
Language: English
Published by Apple Academic Pr Inc, 2023
- Hardcover
- New

Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
US$ 302.85
Quantity: 2 available
Add to basketItem description from seller
294 pages. 9.19x6.13x0.71 inches. In Stock.
Seller Inventory # x-1774912775
- Title
- Drug Repurposing and Computational Drug Discovery: Strategies and Advances
- Author
- Rudrapal, Mithun (Editor)
- Publisher
- Apple Academic Pr Inc
- Publication year
- 2023
- Condition
- Brand New
- Binding
- Hardcover
- Language
- English
- ISBN 10
- 1774912775
- ISBN 13
- 9781774912775
- Item weight
- 0.7 kilograms
Drug repurposing is defined as identifying new pharmacological indications from old, existing, failed, investigational, already marketed, or FDA-approved drugs and prodrugs, and applying these new uses in the treatment of diseases other than the drug’s original intended therapeutic use. The application of computational techniques in discovery research not only helps in the development of drugs from leads or existing drug molecules but can also be useful for the repurposing of existing drug candidates.
This new volume presents exciting recent advances in drug repurposing and computational approaches for the discovery and development of drugs against certain difficult-to-treat and life-threatening diseases. With contributions from a global team of experts (academicians, scientists, and researchers), it explores the sophisticated tools and techniques of drug repurposing and computational drug discovery. It delivers valuable information on computational techniques, tools, and databases being utilized for drug repurposing and for identifying the uses of existing drug candidates on different emerging or deadly diseases. Drug repurposing and computational approaches addressed in the book target the discovery and development of drugs for microbial infections (bacterial, fungal, viral, COVID-19), parasitic diseases and neglected tropical diseases (NTDs), malignant diseases (cancer), inflammatory diseases, cardiovascular disorders, diabetes, and aging and neurological (CNS) disorders. In addition, the challenges and regulatory issues encountered in drug repurposing and computational drug discovery programs are looked at, offering perspectives for future directions.
"Synopsis" may belong to another edition of this title.
About the Author
Mithun Rudrapal, PhD, FIC, FICS, CChem (India), is Associate Professor at the Department of Pharmaceutical Sciences, School of Biotechnology & Pharmaceutical Sciences, Vignan’s Foundation for Science, Technology and Research (Deemed to be University), Guntur, India. Dr. Rudrapal has been actively engaged in teaching and research the field of pharmaceutical and allied sciences for more than 12 years. He has over 100 publications in peer-reviewed international journals to his credit and has filed a number Indian and international patents. In addition, Dr. Rudrapal is the author of dozen published or forthcoming books. Dr. Rudrapal works in the areas of medicinal chemistry, cadd, drug repurposing, phytochemistry, herbal drugs, and nanophytotherapeutics.
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | US$ 16.64 | US$ 39.93 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Shipping terms
Orders usually dispatched within two working days. Please note that at this time all domestic United Kingdom orders are sent by trackable UPS courier, we choose not to offer a lower cost alternative.